Apr. 13 at 1:46 AM
Has anyone digested Ocular's presentation yesterday at Vit-Buckle Society?? We're cooked. They used Assay-Quant Kinome Tree data (Pages 13-16) to systematically dismantle Vorolanib. They demonstrated that at actual physiologic conditions in the eye, Axitinib achieves near 100% inhibition across VEGFR1, 2, and 3. In stark contrast, they highlighted that Vorolanib only achieves 30% to 50% inhibition.
Ocular is trying to kill the competitive threat at the MOLECULAR level before
$EYPT even files their own data.
https://investors.ocutx.com/static-files/25f7136d-a534-4d93-8884-614e88408879
